Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice

International Journal of Oncology

Volumn 14, Issue 2, 1999, Pages 245-251

  Cesano, Alessandra ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

111indium oxine labeled effector cells; Immunocompetent mice; Organ distribution; SCID mice; Tumor homing

Indexed keywords

INDIUM;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; CELL LINE; CELL MOTION; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NATURAL KILLER CELL; PATHOLOGY; TRANSPLANTATION; XENOGRAFT;

ANIMALS; CELL LINE; CELL MOVEMENT; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDIUM RADIOISOTOPES; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033074461     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.2.245     Document Type: Article

References (15)

1. Cesano A and Santoli D: Two unique human leukemic T-cell lines endowed with stable cytotoxic function and different spectrum of target reactivity. Analysis and modulation of their lytic mechanisms. In yitro Cell Dev Biol 28A: 648-656, 1992.
2. Cesano A and Santoli D: Inducible expression of granulocytemacrophage colony-stimulating factor, tumor necrosis factor-α, and interferon-γ in two human cytotoxic leukcmic T cell lines. In Vitro Cell Dev Biol 28A: 657-662, 1992.
3. Cesano A, Visonneau S, Clark SC and Santoli D: Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-12. J Immunol 151: 2943-2957, 1993.
4. Cesano A, Visonneau S, Cioé L, Clark SC and Santoli D: Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T-cell clone with potential usefulness in cancer therapy. Cancer Immunol Immunother 40: 139-151, 1995.
5. Cesano A, Visonneau S, Cioé L, Clark SC, Rovera G and Santoli D: Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J Clin Invest 94: 1076-1084, 1994.
6. Cesano A, Visonneau S and Santoli D: Treatment of experimental clioblastoma with a human MHC non-restricted cytotoxic T-cell line. Cancer Res 55: 96-101, 1995.
7. Cesano A, Pierson G, Visonneau S, Migliaccio AR and Santoli D: Use of a lethally irradiated major histocompatibility complex non-restricted cytotoxic T-cell line for effective purging of lysis-sensitive and -resistant leukemic targets. Blood 87: 393-403, 1996.
8. Cesano A, Visonneau S, Pasquini S, Rovera G and Santoli D: Anti-tumor efficacy of a human MHC non-restricted cytotoxic T cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia. Cancer Res 56: 4444-4452, 1996.
9. Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K, Reese L and Santoli D: Phase I clinical trial with a human major histocompatibility complex non-restricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors. Cancer Res 56: 3021-3029, 1996.
10. Cesano A, Visonncau S, Rovera G and Santoli D: Synergistic effects of adriamycin and TALL-104 cell therapy against a human castric carcinoma in vivo. Anticancer Res 17: 1887-1892, 1997.
11. Visonneau S, Cesano A, Torosian M and Santoli D: Cell therapy of a highly invasive human breast carcinoma implanted in iinmunodeficient (SCID) mice. Clin Cancer Res 3: 1491-1500, 1997.
12. Visonneau S, Cesano A, Tran T, Jeglum KA and Santoli D: Successful treatment of canine malignant histiocytosis with the human MHC non-restricted cytotoxic T cell line TALL-104. Clin Cancer Res 3: 1789-1797, 1997.
13. Cesano A, Visonneau S and Santoli D: TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice. Anticancer Res 18: 2289-2295, 1998.
14. Visonncau S, Cesano A, Torosian MH, Miller EJ and Santoli D: Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice. Am J Pathol 152: 1299-1311, 1988.
15. Kundu N, Beaty TL, Jackson MJ and Fulton AM: Antimetastatic and antitumor activities of intcrleukin 10 in a murine model of breast cancer. J Natl Cancer Inst 88: 536-541, 1996.